



## **VIVUS Announces QSYMIA® Price Reduction at Costco Pharmacies Nationwide**

*— Lowered price at retail pharmacy to expand access to overweight or obesity treatment to more patients*

CAMPBELL, Calif., OCTOBER 8, 2025, (GLOBE NEWSWIRE) – VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced the price of QSYMIA® (phentermine and topiramate extended-release capsules CIV) available via Costco Member Prescription Program at Costco Pharmacies nationwide (prescription required), has been lowered to less than \$99 for all doses effective October 1.

“At VIVUS, our mission has always been to expand access to innovative therapies that can make a meaningful difference in people’s lives,” said John Amos, Chief Executive Officer at VIVUS LLC. “With the growing demand for weight-loss medications, affordability and access have become more important than ever. While other treatments, like Ozempic and Wegovy, are available at a higher price point, our partnership with Costco enables patients to access QSYMIA for under \$99. This makes QSYMIA one of the most cost-effective, clinically proven options for weight management. Together with Costco, we’re expanding access to effective therapy and helping more patients take meaningful steps toward better health.”

The price reduction through the Costco Member Prescription Program makes QSYMIA more accessible to patients. Combined with the convenience of Costco Pharmacies, this lower cost provides patients with greater choice and flexibility when selecting a weight-loss medication. With this update, a 30-day supply of QSYMIA is available for less than \$99.00. Claims submitted for coverage under publicly funded programs (e.g. Medicare, Medicaid, etc.) or private insurance are not eligible for Costco Member Prescription Program participation.

“At Costco Pharmacy, we are focused on delivering meaningful value by combining affordability, convenience, and quality care for our members,” said Chris Pierce, Assistant Vice President, Costco. “In partnership with VIVUS, we are expanding access to QSYMIA at a lower cost, helping patients more easily obtain the treatment they need and improve their health outcomes. By passing these savings directly to our members, we strengthen our commitment to ensuring patients have affordable access to the therapies they rely on.”

QSYMIA is the leading non-injectable branded weight loss medication in the U.S. for adults. QSYMIA is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight in some adults and certain pediatric patients aged 12 years and older.

### **About VIVUS**

VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit <http://www.vivus.com>.

### **About QSYMIA**

QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.

The effect of QSYMIA on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSYMIA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

For more information on QSYMIA, please visit <https://QSYMIA.com/>

### **Important Safety Information for QSYMIA**

Do not take QSYMIA if you are pregnant, planning to become pregnant, or become pregnant during QSYMIA treatment; have glaucoma; have thyroid problems (hyperthyroidism); are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days; are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in QSYMIA.

QSYMIA can cause serious side effects, including birth defects (cleft lip/cleft palate), serious eye problems (secondary angle closure glaucoma), visual field defects (independent of elevated intraocular pressure), suicidal thoughts or actions, and severe rash with blisters and peeling skin. QSYMIA may slow the increase in height in children 12 years and older.

Common side effects of QSYMIA in adults include numbness or tingling in the hands, arms, feet, or face (paraesthesia), dizziness, changes in the way foods taste or loss of taste (dysgeusia), trouble sleeping (insomnia), constipation, and dry mouth. Common side effects of QSYMIA in children aged 12 years and older include depression, dizziness, joint pain, fever, flu, and ankle sprain.

For more information, please read the QSYMIA Medication Guide, Full Prescribing Information, and Risk of Birth Defects with QSYMIA patient brochure.

### **Forward-Looking Statements**

#### *Important Information and Cautionary Note Regarding Forward-Looking Statements*

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and/or covered by the “Bespeaks Caution” doctrine applied by the courts under the antifraud provisions of the federal securities laws, and other applicable provisions of the federal securities laws. Such forward-looking statements are based on current expectations, management’s beliefs and certain assumptions made by the Company’s management. These statements may be identified by the use of forward-looking words such as “will,” “shall,” “may,” “believe,” “expect,” “forecast,” “intend,” “anticipate,” “predict,” “should,” “plan,” “likely,” “opportunity,” “estimated,” and “potential,” and/or the negative use of these words or other similar words. All forward-looking statements included in this document are based on our current expectations, and the Company assumes no obligation to update any such forward-looking statements except to the extent otherwise required by law.*

*Forward-looking information about QSYMIA, including its potential benefits, approvals in potential markets outside the U.S. and anticipated product availability, involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied in this press release. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any other markets or approved, whether QSYMIA will be commercially successful; decisions by*



*regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of QSYMIA; uncertainties regarding the impact of COVID-19 on our business, operations, and financial results; and competitive developments.*

*The above factors, risks and uncertainties are difficult to predict, contain uncertainties that may materially affect actual results and may be beyond the Company's control. New factors, risks and uncertainties emerge from time to time, and it is not possible for management to predict all such factors, risks and uncertainties. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore any of these statements may prove to be inaccurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by the Company or any other person that the Company's objectives and plans will be achieved. These forward-looking statements speak only as of the date such statements were made or any earlier date indicated, and the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in underlying assumptions or otherwise, unless otherwise required by law.*

## **Contacts**

### **VIVUS LLC**

T: +1 (650) 934-5200

### **Media – FINN Partners**

Glenn Silver

[glenn.silver@finnpartners.com](mailto:glenn.silver@finnpartners.com)

T: +1 973-818-8198